Pulmonary zygomycosis in solid organ transplant recipients in the current era

Am J Transplant. 2009 Sep;9(9):2166-71. doi: 10.1111/j.1600-6143.2009.02754.x. Epub 2009 Jul 22.


Fifty-eight solid organ transplant recipients with zygomycosis were studied to assess the presentation, radiographic characteristics, risks for extra-pulmonary dissemination and mortality of pulmonary zygomycosis. Pulmonary zygomycosis was documented in 31 patients (53%) and developed a median of 5.5 months (interquartile range, 2-11 months) posttransplantation. In all, 74.2% (23/31) of the patients had zygomycosis limited to the lungs and 25.8% (8/31) had lung disease as part of disseminated zygomycosis; cutaneous/soft tissue (50%, 4/8) was the most common site of dissemination. Pulmonary disease presented most frequently as consolidation/mass lesions (29.0%), nodules (25.8%) and cavities (22.6%). Patients with disseminated disease were more likely to have Mycocladus corymbifer as the causative pathogen. The mortality rate at 90 days after the treatment was 45.2%. In summary, pulmonary zygomycosis is the most common manifestation in solid organ transplant recipients with zygomycosis, and disseminated disease often involves the cutaneous/soft tissue sites but not the brain.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antifungal Agents / therapeutic use
  • Female
  • Humans
  • Lung Diseases, Fungal / drug therapy*
  • Lung Diseases, Fungal / etiology*
  • Male
  • Middle Aged
  • Organ Transplantation / adverse effects*
  • Postoperative Complications / drug therapy
  • Time Factors
  • Treatment Outcome
  • Zygomycosis / drug therapy*
  • Zygomycosis / etiology*


  • Antifungal Agents